Skip to main content

Table 2 Results of Cox regression analysis

From: Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer

Disease-free survival variables

 

Univariable analysis

Multivariable analysis

 

HR

(95% CI)

p Value

HR

(95% CI)

p Value

 Tumor size

< 4 cm

1

0.6

1

0.2

≥ 4 cm

1.35

(0.43 to 4.19)

0.43

(0.09 to 1.94)

 Nuclear grade

1/2

1

0.9

1

0.06

3

1

(0.28 to 3.56)

0.15

(0.02 to 1.13)

 ER

+

1

0.03

1

0.03

–

3.72

(1.12 to 12.3)

7.53

(1.17 to 48.33)

 Nodal involvement

–

1

0.09

1

0.4

+

5.75

(0.74 to 44.2)

2.25

(0.25 to 19.9)

 FMISO-TBR

< 1.48

1

0.002

1

0.005

≥ 1.48

5.72

(1.83 to 17.82)

11.35

(2.07 to 62.23)

 Chemotherapy

 

1

0.9

N/A

+

368,675.3

(5.3E-168 to 25.4E + 177)

Overall survival variables

 

Univariable analysis

Multivariable analysis

 

HR

(95% CI)

p Value

HR

(95% CI)

p Value

 Tumor size

< 4 cm

1

0.6

1

0.7

≥ 4 cm

1.45

(0.29 to 7.15)

0.71

(0.1 to 4.71)

 Nuclear grade

1/2

1

0.9

1

0.2

3

1.09

(1.18 to 6.57)

0.21

(0.01 to 2.82)

 ER

+

1

0.2

1

0.1

–

3.03

(0.55 to 16.5)

10.24

(0.57 to 181.96)

 Nodal involvement

–

1

0.9

1

0.9

+

411,595.95

(9.7E-202 to 1.74E + 210)

141,679.29

(7.17E-223 to 27.97E + 231)

 FMISO-TBR

< 1.48

1

0.06

1

0.1

≥ 1.48

4.43

(0.88 to 22.17)

7.59

(0.63 to 90.68)

 Chemotherapy

 

1

0.9

N/A

+

122,960.7

(6.7E-167 to 222.6E + 174)

  1. Abbreviations: FMISO 18F-fluoromisonidazole, ER Estrogen receptor, TBR Tissue-to-blood ratio